Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has ...
Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent clinical study. D23 is budesonide ...
NANJING, China--(BUSINESS WIRE)--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent ...
Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN ...
Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...
The Society for Clinical Research Sites (SCRS) and Fortrea , a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward ...
If you're not happy with the results, please do another search.
NANJING, China--(BUSINESS WIRE)--#3DPrintingPharmaceutical--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive ...